Meeting
2022 ASCO Annual Meeting
Donor-derived T cells specific for tumor antigen and multiple pathogens for prevention of relapse and infection after haemopoietic stem cell transplant (HSCT) for myeloid malignancies (the INTACT trial).
Authors
Wei Jiang
The Westmead Institute for Medical Research, The University of Sydney, Westmead, Australia
Wei Jiang , Gaurav Sutrave , Abir Bhattacharyya , Peter J. Shaw , Caroline M. Bateman , Selmir Avdic , Leighton E. Clancy , Janine Street , Elissa Atkins , Kenneth Micklethwaite , David Gottlieb , Emily Blyth
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT02895412
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7039)
DOI
10.1200/JCO.2022.40.16_suppl.7039
Abstract #
7039
Poster Bd #
270
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
An analysis of a first-in-human study of NEXI-001 donor-derived antigen-specific CD8+ T-cell treatment of relapsed AML after allogeneic hematopoietic cell transplantation (HCT).
First Author: Monzr M. Al Malki
First Author: Ibrahim Yakoub-Agha
Poster
2012 ASCO Annual Meeting
Allogeneic stem cell transplantation for patients over age 65 with acute myelogenous leukemia and myelodysplastic syndrome.
First Author: Henry Jacob Conter
Poster
2023 ASCO Annual Meeting
Effect of disease status prior to T-cell depleted allogeneic stem cell transplantation on relapse-free and overall survival in patients with adverse-risk acute myeloid leukemia (AML).
First Author: Alexandra Ewa Rojek